Baiji Shenzhou, an innovative anti-tumor drug R & D company, obtained a financing of RMB 600 million

Baiji Shenzhou is an innovative anti-tumor company, mainly engaged in tumor targeting and tumor immunotherapy Today, the company has successfully secured 970m of financing Companies involved in the financing include existing investors Hillhouse capital, CITIC Industrial Fund, an unnamed US blue chip mutual fund (mainly focusing on Life Science), and other existing investors They have always been confident in the company There are also new investors in this round of financing, including Fidelity Management & research company, T Rowe price & Associates, Rock Springs capital management, and Boxer capital of Tavistock life sciences Baiji Shenzhou plans to use this round of financing for the follow-up research and development of anti-cancer candidate drugs, expand the scale of its international clinical research and development team, improve its research and development capacity, and strengthen drug production John v oyler, CEO of the company, said: "we are very happy to have the support and help of existing investors and to have such high-level investors to join us It's gratifying that these companies are able to tap into our unique potential We hope to cooperate with investors in the stage of rapid expansion of clinical trials Our research and transformation platform is continuing to develop exciting targeted and immunoanticancer drugs, which have the potential to become world-class drugs The field of anti-tumor is changing with each passing day It is moving towards the direction of combined treatment to bring better medical services for patients We believe that both targeting and immunoantitumor play a key role in this regard "At present, three small molecular inhibitors in Baiji Shenzhou have entered the first phase of clinical trials: tyrosine kinase inhibitor bgb-3111, which is in the development stage and can be taken orally with high selectivity; second generation B-Raf inhibitor bgb-283; ADP ribose polymerase inhibitor bgb-290 The company is also actively involved in preclinical research, such as bgb-108, a highly effective and highly selective candidate drug for PD-1 monoclonal antibody, which is expected to enter clinical trials this year Michael Yi from Hillhouse capital said: "Baiji Shenzhou has always been pursuing innovation It not only has leading biotechnology and superior geographical environment, but also continuously tries different clinical projects Although the tumor treatment program changes rapidly, but also very understanding of the current situation Tang Ke, vice president of CITIC industry fund, commented: China will invest more and more in new drug R & D, with low R & D costs and sufficient human resources with high education, all of which are advantages Baiji Shenzhou creatively combines its world-class drug R & D capability with China's R & D platform We hope to continue to support Baiji and make greater progress "About Baiji Shenzhou: Baiji Shenzhou is an innovative anti-tumor drug R & D company, mainly involving the R & D and sales of targeted and immunoanti-tumor treatment The company has two advantages of new transformation research platform, i.e its biological anti-tumor advantages and a large number of clinical tumor tissue visual examination samples Mainly engaged in oral small molecule drugs, monoclonal antibody research and development, through the combination of drugs to achieve better therapeutic effect.